24 results on '"Milica M. Borovcanin"'
Search Results
2. Galectin-3 Involvement in Cognitive Processes for New Therapeutic Considerations
- Author
-
Nataša R. Mijailović, Katarina Vesic, Dragana Arsenijevic, Maja Milojević-Rakić, and Milica M. Borovcanin
- Subjects
galectin-3 ,cognition ,neuroinflammation ,neurodegeneration ,galectin-3 inhibition ,microglia ,Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 - Abstract
Cognitive impairment may be a consequence of the normal aging process, but it may also be the hallmark of various neurodegenerative and psychiatric diseases. Early identification of individuals at particular risk for cognitive decline is critical, as it is imperative to maintain a cognitive reserve in these neuropsychiatric entities. In recent years, galectin-3 (Gal-3), a member of the galectin family, has received considerable attention with respect to aspects of neuroinflammation and neurodegeneration. The mechanisms behind the putative relationship between Gal-3 and cognitive impairment are not yet clear. Intrigued by this versatile molecule and its unique modular architecture, the latest data on this relationship are presented here. This mini-review summarizes recent findings on the mechanisms by which Gal-3 affects cognitive functioning in both animal and human models. Particular emphasis is placed on the role of Gal-3 in modulating the inflammatory response as a fine-tuner of microglia morphology and phenotype. A review of recent literature on the utility of Gal-3 as a biomarker is provided, and approaches to strategically exploit Gal-3 activities with therapeutic intentions in neuropsychiatric diseases are outlined.
- Published
- 2022
- Full Text
- View/download PDF
3. The Influence of Serum Uric Acid on the Brain and Cognitive Dysfunction
- Author
-
Natasa R. Mijailovic, Katarina Vesic, and Milica M. Borovcanin
- Subjects
uric acid ,cognition ,neuroprotection ,neurotoxicity ,oxidative stress ,inflammation ,Psychiatry ,RC435-571 - Abstract
Uric acid is commonly known for its bad reputation. However, it has been shown that uric acid may be actively involved in neurotoxicity and/or neuroprotection. These effects could be caused by oxidative stress or inflammatory processes localized in the central nervous system, but also by other somatic diseases or systemic conditions. Our interest was to summarize and link the current data on the possible role of uric acid in cognitive functioning. We also focused on the two putative molecular mechanisms related to the pathological effects of uric acid—oxidative stress and inflammatory processes. The hippocampus is a prominent anatomic localization included in expressing uric acid's potential impact on cognitive functioning. In neurodegenerative and mental disorders, uric acid could be involved in a variety of ways in etiopathogenesis and clinical presentation. Hyperuricemia is non-specifically observed more frequently in the general population and after various somatic illnesses. There is increasing evidence to support the hypothesis that hyperuricemia may be beneficial for cognitive functioning because of its antioxidant effects but may also be a potential risk factor for cognitive dysfunction, in part because of increased inflammatory activity. In this context, gender specificities must also be considered.
- Published
- 2022
- Full Text
- View/download PDF
4. Targeting Underlying Inflammation in Carcinoma Is Essential for the Resolution of Depressiveness
- Author
-
Milica M. Borovcanin, Katarina Vesić, Dragana Arsenijević, Maja Milojević-Rakić, Nataša R. Mijailović, and Ivan P. Jovanovic
- Subjects
carcinoma ,depression ,acute inflammation ,chronic inflammation ,drug-treatment ,Cytology ,QH573-671 - Abstract
In modern clinical practice and research on behavioral changes in patients with oncological problems, there are several one-sided approaches to these problems. Strategies for early detection of behavioral changes are considered, but they must take into account the specifics of the localization and phase in the course and treatment of somatic oncological disease. Behavioral changes, in particular, may correlate with systemic proinflammatory changes. In the up-to-date literature, there are a lot of useful pointers on the relationship between carcinoma and inflammation and between depression and inflammation. This review is intended to provide an overview of these similar underlying inflammatory disturbances in both oncological disease and depression. The specificities of acute and chronic inflammation are considered as a basis for causal current and future therapies. Modern therapeutic oncology protocols may also cause transient behavioral changes, so assessment of the quality, quantity, and duration of behavioral symptoms is necessary to prescribe adequate therapy. Conversely, antidepressant properties could be used to ameliorate inflammation. We will attempt to provide some impetus and present some unconventional potential treatment targets related to inflammation. It is certain that only an integrative oncology approach is justifiable in modern patient treatment.
- Published
- 2023
- Full Text
- View/download PDF
5. Uric Acid Potential Role in Systemic Inflammation and Negative Symptoms After Acute Antipsychotic Treatment in Schizophrenia
- Author
-
Milica M. Borovcanin, Slavica Minic Janicijevic, Natasa R. Mijailovic, Ivan P. Jovanovic, Nebojsa N. Arsenijevic, and Katarina Vesic
- Subjects
uric acid ,schizophrenia ,cytokines ,interleukin-6 ,interleukin-17 ,Psychiatry ,RC435-571 - Abstract
Uric acid (UA) has been shown to have neuroprotective or neurotoxic properties, in relation to specific tissues and diseases that have been studied. Previous studies provided contradictory results on the role of UA in schizophrenia as a neurodegenerative disorder. The aim of this brief report was an additional analysis of UA sera levels in different phases of schizophrenia. Here, 86 patients with first-episode psychosis (FEP) vs. 45 patients with schizophrenia in relapse (SC in relapse) vs. 35 healthy control subjects (HC) were studied before and 1 month after antipsychotic therapy. Further, we aimed to explore the possible correlation of UA with scores presenting clinical features and with serum concentrations of the proinflammatory cytokines interleukin (IL)-6 and IL-17. When comparing the data between all three groups, we did not find significant differences in UA levels, either before or after the applied therapy. Also, comparing sera concentrations of UA in every single group, the analysis did not reveal statistically significant differences between FEP patients, but statistically, a significant difference was found in SC in relapse before and after treatment (334.71 ± 116.84 vs. 289.37 ± 109.15 μmol/L, p = 0.05). Uric acid serum levels correlated with negative sub-score (p = 0.001, r = 0.306), general sub-score (p = 0.015, r = 0.236), and total PANSS score (p = 0.009, r = 0.3) after 1 month of therapy. We have established a statistically significant positive correlation between serum concentrations of UA and IL-6 in exacerbation (p = 0.01, r = 0.220) and with IL-17 after treatment and in the stabilization of psychosis (p = 0.01, r = 0.34), suggesting potential cascades in different phases of schizophrenia that potentiate inflammation.
- Published
- 2022
- Full Text
- View/download PDF
6. Psychiatry Trainees' Attitudes, Knowledge, and Training in Addiction Psychiatry—A European Survey
- Author
-
Laura Orsolini, Irena Rojnić Palavra, Gabriele Duccio Papanti, Matej Potočan, Diego Quattrone, Matis Martens, Sandra Sklenářová, Jonna Levola, Leslie Grichy, Sean Naughton, Indre Kotryna Grinevičiene, Jelly Petra Kuiters, Tomasz M. Gondek, Anca-Livia Panfil, Milica M. Borovcanin, Alberto San Roman Uria, Ewelina Biskup, Ekin Sönmez Güngör, Marisa Casanova Dias, Sonila Tomori, Visnja Banjac, Petra Marinova-Djambazova, and Mariana Pinto da Costa
- Subjects
addiction psychiatry ,addiction ,EFPT ,psychiatry trainees ,psychiatry training ,Psychiatry ,RC435-571 - Abstract
Background: Although psychoactive substance use disorders (PSUDs) are a domain of mental health, addiction psychiatry is only formally recognized as a subspecialty in a few European countries, and there is no standardized training curriculum.Methods: A 76-item questionnaire was developed and disseminated through an online anonymous data-collecting system and hand-to-hand amongst psychiatric trainees from the 47 European countries of the Council of Europe plus Israel and Belarus.Results: 1,049/1,118 psychiatric trainees from 30 European countries completed the questionnaire. Fifty-nine-point nine percent of trainees stated to have training in addictions. Amongst the trainees who described having training in addictions, 43% documented a not well-structured training and 37% an unsatisfactory training, mainly due to poor acquired knowledge. Overall, 97% of trainees stated that addiction represents a core curriculum for their training. Overall, general adult psychiatric trainees reported a better knowledge in addictions, compared to trainees in child and adolescent psychiatry.Conclusion: Despite a growing spread of PSUDs in European countries, addiction psychiatry is a relatively poorly trained field within psychiatry training programs. Further research should investigate reasons for poor training and timings of the educational activities to optimize experiential education training in addiction psychiatry.
- Published
- 2021
- Full Text
- View/download PDF
7. Chlorpromazine as a Potential Antipsychotic Choice in COVID-19 Treatment
- Author
-
Nemanja N. Muric, Nebojsa N. Arsenijevic, and Milica M. Borovcanin
- Subjects
chlorpromazine ,SARS-CoV-2 ,COVID-19 ,psychosis ,infection ,Psychiatry ,RC435-571 - Published
- 2020
- Full Text
- View/download PDF
8. Type 17 Immune Response Facilitates Progression of Inflammation and Correlates with Cognition in Stable Schizophrenia
- Author
-
Milica M. Borovcanin, Slavica Minic Janicijevic, Ivan P. Jovanovic, Nevena M. Gajovic, Milena M. Jurisevic, and Nebojsa N. Arsenijevic
- Subjects
schizophrenia ,cognition ,IL-17 ,CD4+ T cells ,CD56+ NK cells ,Medicine (General) ,R5-920 - Abstract
Dysregulation of the type 17 immune pathway has already been considered in schizophrenia and we previously measured decreased sera values of interleukin (IL)-17 in early stages. We further explored the possible correlation of IL-17 systemic levels with proinflammatory cytokines and cognitive scores and additionally analyzed the percentage of IL-17 producing lymphocytes in peripheral blood of patients with stable schizophrenia. We included 27 patients diagnosed with schizophrenia (F20), after a three-month stable depot antipsychotic therapy (risperidone or paliperidone) and 18 healthy control subjects. Positive and Negative Syndrome Scale of Schizophrenia and the Montreal-Cognitive Assessment (MoCA) were conducted. Sera concentrations of IL-17, IL-6, tumor necrosis factor alpha (TNF-α) and soluble ST2 receptor (sST2) were measured. Flow cytometry and Natural Killer (NK) and T cell analyses were done in 10 patients and 10 healthy controls. Moderate positive correlation was established between IL-17 and TNF-α (r = 0.640; p = 0.001), IL-17 and IL-6 (r = 0.514; p = 0.006), IL-17 and sST2 (r = 0.394; p = 0.042). Furthermore, a positive correlation between the serum levels of IL-17 and MoCA scores was observed, especially with visuospatial and executive functioning, as well as language functioning and delayed recall (p < 0.05). Significantly higher percentage of IL-17 producing CD56+ NK cells was measured in peripheral blood of patients with schizophrenia in remission vs. healthy individuals (p = 0.001). The percentage of CD4+ T cells and CD4+ T cells that produce IL-17 was significantly increased in patients (p = 0.001). This study revealed the involvement of innate type 17 immune response in the progression of inflammation and this could be related to cognitive functioning in stable schizophrenia.
- Published
- 2020
- Full Text
- View/download PDF
9. IL-33/ST2 Pathway and Galectin-3 as a New Analytes in Pathogenesis and Cardiometabolic Risk Evaluation in Psychosis
- Author
-
Milica M. Borovcanin, Slavica M. Janicijevic, Ivan P. Jovanovic, Nevena Gajovic, Nebojsa N. Arsenijevic, and Miodrag L. Lukic
- Subjects
schizophrenia ,galectin-3 ,interleukin-33 ,metabolic syndrome ,cardiovascular issues ,Psychiatry ,RC435-571 - Abstract
Schizophrenia and treatment of this disorder are often accompanied with metabolic syndrome and cardiovascular issues. Alterations in the serum level of innate immune mediators, such as interleukin-33 (IL-33) and its receptor IL-33R (ST2) and Galectin-3 (Gal-3) were observed in these conditions. Moreover, these parameters are potential prognostic and therapeutic markers. There is also accumulating evidence that these molecules play a role in neuroinflammation. Therefore, in this study we have investigated the serum level of Gal-3, IL-33 and soluble ST2 (sST2) in different stages of schizophrenia. Gal-3 levels were elevated in remission and lower in schizophrenia exacerbation in comparison with controls. Levels of IL-33 and sST2 are higher in schizophrenia exacerbation in comparison with controls and patients in remission. This initial analysis of new markers of neuroinflammation suggested their involvement in schizophrenia pathophysiology and/or cardiometabolic comorbidity.
- Published
- 2018
- Full Text
- View/download PDF
10. Diabetes mellitus type 2 as an underlying, comorbid or consequent state of mental disorders
- Author
-
Milica M Borovcanin, Katarina Vesic, Ivica Petrovic, Ivan P Jovanovic, and Nataša R Mijailović
- Subjects
Endocrinology, Diabetes and Metabolism ,Internal Medicine - Published
- 2023
11. Neuroimmune, clinical and treatment challenges in multiple sclerosis-related psychoses
- Author
-
Katarina Vesic, Aleksandar Gavrilovic, Nataša R Mijailović, and Milica M Borovcanin
- Subjects
General Earth and Planetary Sciences ,General Environmental Science - Published
- 2023
12. Galectin-3 mediated risk of inflammation in stable schizophrenia, with only possible secondary consequences for cognition
- Author
-
Slavica Minic Janicijevic, Ivan P Jovanovic, Nevena M Gajovic, Milena M Jurisevic, Monojit Debnath, Nebojsa N Arsenijevic, and Milica M Borovcanin
- Subjects
General Earth and Planetary Sciences ,General Environmental Science - Abstract
Evidence suggests that cytokines cause immune disturbances, shape immunological sequelae later in life, and modulate the risk of schizophrenia (SC). Galectin-3 (Gal-3), a multifaceted molecule of the glycan family, is involved in the formation of the immunological synapse and modulates the signalling pathway and effector functions of T lymphocytes, which are major producers of cytokines. We have previously reported elevated serum Gal-3 levels in stable SC patients. However, Gal-3 as a link between cognitive functioning and inflammation has not yet been investigated in SC.To investigate the relationship between serum Gal-3 levels and cognitive performance, serum cytokines, and white blood cell count in three-month stably treated SC patients.Twenty-seven patients with SC in remission and 18 healthy volunteers participated in this case-control and correlational study. Clinical assessment was performed using the Positive and Negative Syndrome Scale and the Montreal-Cognitive Assessment. The results of previously measured serum levels of Gal-3, interleukin (IL)-33, soluble suppression of tumorigenicity 2 (sST2), tumor necrosis factor-alpha (TNF-α), IL-6 and IL-17 were used for further statistical analyses, and IL-4, IL-23, IL-1β and transforming growth factor-beta (TGF-β) were now additionally measured with a sensitive enzyme-linked immunosorbent assay. The number of leukocytes in the blood and the percentage of neutrophils, lymphocytes, and monocytes were determined with a standardized routine measurement procedure (Sysmex Technology). Statistical analyses were performed using SPSS 20.0 software.We found no correlation between serum Gal-3 levels and cognitive functioning in SC patients. A positive correlation was found between the levels of Gal-3 and TNF-α (The combined activity of Gal-3 and proinflammatory cytokines, TGF-β downregulation and lower counts of leukocytes influence the SC duration. Gal-3 likely manifests indirect immunometabolic regulation of cognition in SC.
- Published
- 2022
13. Targeting Underlying Inflammation in Carcinoma Is Essential for the Resolution of Depressiveness
- Author
-
Ivan Jovanovic, Milica M. Borovcanin, Katarina Vesić, Dragana Arsenijevic (Djordjevic), Nataša R Mijailović, and Maja Milojević-Rakić
- Subjects
General Medicine - Abstract
In modern clinical practice and research on behavioral changes in patients with oncological problems, there are several one-sided approaches to these problems. Strategies for early detection of behavioral changes are considered, but they must take into account the specifics of the localization and phase in the course and treatment of somatic oncological disease. Behavioral changes, in particular, may correlate with systemic proinflammatory changes. In the up-to-date literature, there are a lot of useful pointers on the relationship between carcinoma and inflammation and between depression and inflammation. This review is intended to provide an overview of these similar underlying inflammatory disturbances in both oncological disease and depression. The specificities of acute and chronic inflammation are considered as a basis for causal current and future therapies. Modern therapeutic oncology protocols may also cause transient behavioral changes, so assessment of the quality, quantity, and duration of behavioral symptoms is necessary to prescribe adequate therapy. Conversely, antidepressant properties could be used to ameliorate inflammation. We will attempt to provide some impetus and present some unconventional potential treatment targets related to inflammation. It is certain that only an integrative oncology approach is justifiable in modern patient treatment.
- Published
- 2023
14. Contributors
- Author
-
Ian M. Adcock, Veronica Adiletta, Ramapraba Appanna, Carmen Busca Arenzana, Aleksandar N. Arsenijevic, Nebojsa N. Arsenijevic, Ángel Ayuso-Sacido, Jose I. Bernardino, Milica M. Borovcanin, Tanima Bose, Gaetano Caramori, Josefa Carrión-Navarro, Vincenzo Casolaro, Xiaoyan Chen, Dinh-Toi Chu, Jacqueline Pui Wah Chung, Francesca Cillo, Emilia Cirillo, Noemí García-Romero, Leonardo Garcia-Velazquez, Andrew R. Gennery, Giuliana Giardino, Ankmalika Gupta, Sudhir Gupta, Md Abdul Hannan, Phil M. Hansbro, null Hasan-Al-Faruque, Rodrigo Kern, Paul Kirkham, Ourania S. Kotsiou, Nguyen Thanh Lam, Paolo Maria Leone, Tin Chiu Li, Chit Tong Lio, Kalaivani Manibarathi, Angel Robles Marhuenda, Jelena Milovanovic, Marija Milovanovic, Akhi Moni, Mahdieh-Sadat Moosavi, Nemanja N. Muric, Vo Truong Nhu Ngoc, Francesco Nucera, Leticia Madureira Pacholak, Irina Palacín-Aliana, Carolina Panis, Keshav Raj Paudel, Claudio Pignata, Rosaria Prencipe, Md. Ataur Rahman, Nima Rezaei, Roberta Romano, Veronica De Rosa, Luis Ramos Ruperto, Domenico Sambataro, Gianluca Sambataro, Thalita Basso Scandolara, Davood Shafie, Isabella Morais Tavares, Elisabetta Toriello, Dang Khoa Tran, Md Jamal Uddin, Katarina Vesic, Chi Chiu Wang, Niloufar Yazdanpanah, and Tao Zhang
- Published
- 2022
15. Psychiatry Trainees' Attitudes, Knowledge, and Training in Addiction Psychiatry-A European Survey
- Author
-
Laura Orsolini, Irena Rojnić Palavra, Gabriele Duccio Papanti, Matej Potočan, Diego Quattrone, Matis Martens, Sandra Sklenářová, Jonna Levola, Leslie Grichy, Sean Naughton, Indre Kotryna Grinevičiene, Jelly Petra Kuiters, Tomasz M. Gondek, Anca-Livia Panfil, Milica M. Borovcanin, Alberto San Roman Uria, Ewelina Biskup, Ekin Sönmez Güngör, Marisa Casanova Dias, Sonila Tomori, Visnja Banjac, Petra Marinova-Djambazova, Mariana Pinto da Costa, HUS Psychiatry, Clinicum, Department of Psychiatry, and HUS Helsinki and Uusimaa Hospital District
- Subjects
medicine.medical_specialty ,lcsh:RC435-571 ,PROFESSIONALS ,media_common.quotation_subject ,education ,Experiential education ,ALCOHOL ,Subspecialty ,SUBSTANCE USE DISORDERS ,3124 Neurology and psychiatry ,03 medical and health sciences ,0302 clinical medicine ,PHYSICIANS ,PEOPLE ,lcsh:Psychiatry ,Health care ,medicine ,Child and adolescent psychiatry ,psychiatry training ,030212 general & internal medicine ,Psychiatry ,MENTAL-ILLNESS ,ABUSE ,EFPT ,media_common ,Original Research ,CONSEQUENCES ,business.industry ,Addiction ,STIGMA ,Addiction psychiatry ,psychiatry trainees ,Mental illness ,medicine.disease ,Mental health ,3. Good health ,030227 psychiatry ,Psychiatry and Mental health ,addiction psychiatry ,HEALTH-CARE ,addiction ,business ,Psychology - Abstract
Background: Although psychoactive substance use disorders (PSUDs) are a domain of mental health, addiction psychiatry is only formally recognized as a subspecialty in a few European countries, and there is no standardized training curriculum.Methods: A 76-item questionnaire was developed and disseminated through an online anonymous data-collecting system and hand-to-hand amongst psychiatric trainees from the 47 European countries of the Council of Europe plus Israel and Belarus.Results: 1,049/1,118 psychiatric trainees from 30 European countries completed the questionnaire. Fifty-nine-point nine percent of trainees stated to have training in addictions. Amongst the trainees who described having training in addictions, 43% documented a not well-structured training and 37% an unsatisfactory training, mainly due to poor acquired knowledge. Overall, 97% of trainees stated that addiction represents a core curriculum for their training. Overall, general adult psychiatric trainees reported a better knowledge in addictions, compared to trainees in child and adolescent psychiatry.Conclusion: Despite a growing spread of PSUDs in European countries, addiction psychiatry is a relatively poorly trained field within psychiatry training programs. Further research should investigate reasons for poor training and timings of the educational activities to optimize experiential education training in addiction psychiatry.
- Published
- 2020
16. Peripheral Markers of Immune Response in Major Psychiatric Disorders: Where Are We Now and Where Do We Want to Be?
- Author
-
Milica M. Borovcanin and Bartlomiej Stanczykiewicz
- Published
- 2019
17. Comparison of safety between individualized and empiric dose regimen of amitriptyline in the treatment of major depressive episode
- Author
-
Mihajlovic, Goran, Djukic-Dejanovic, Slavica, Jovanovic-Mihajlovic, Natalija, Jankovic, Slobodan, Janjic, Vladimir, Jovanovic, Mirjana, Petrovic, Dusan, Milica M. Borovcanin, and Radmanovic, Branimir
- Subjects
Depressive Disorder, Major ,Dose-Response Relationship, Drug ,Amitriptyline ,Adverse Drug Reaction Reporting Systems ,Humans ,Bayes Theorem ,Single-Blind Method ,creative psychopharmacotherapy ,individualized treatment ,personalized medicine ,Antidepressive Agents, Tricyclic ,Precision Medicine ,Software - Abstract
To accomplish therapeutic goal it is necessary to adjust the dose of medication to be right for every single patient. This procedure of dose adjustment is individualized dose regimen. First of all, pharmacokinetic aspects should be revised, including parameters such as resorption, distribution, metabolism and secretion of drug. For these purposes, the authors developed and clinically assessed the modified Bayesian method supported by original basic computer program. The aim of research was to compare frequency of adverse events in cases of individualized and empiric dose regimens of amitriptyline in the treatment of major depressive episode. Sixty subjects (32- 65 years old), with major depressive disorder (International Classification of Disease, 10th revision), were randomly assigned and single- blinded to take individualized (experimental group, n=30) or empiric (control group, n=30) doses of amitriptyline for 8 weeks. CGI scale and originally designed questionnaire were used for adverse events assessment. In experimental group, 69 complaints on nine different types of adverse effects were recorded during eight-week treatment period. Severe adverse events, such as confusion or arrhythmia, were not registered in this subgroup. In control group, 111 complaints on twelve different types of adverse effects were recorded. Most common were anticholinergic effects, but during the third and fourth week from baseline, some severe adverse events were observed: tremor (16%), fatigue (16%), in one of the subjects confusion occurred and arrhythmia in another. Analyzing of the results according to CGI scale for adverse events showed that, during the treatment period, adverse events were less frequent in experimental group. This was particularly obvious in the first four weeks of treatment, when statistically significant difference (p
18. Peripheral cytokine alterations through schizophrenia continuance and in somatic comorbidity
- Author
-
Milica M. Borovcanin
19. Positive impact of prescribed physical activity on symptoms of schizophrenia: randomized clinical trial.
- Author
-
Curcic D, Stojmenovic T, Djukic-Dejanovic S, Dikic N, Vesic-Vukasinovic M, Radivojevic N, Andjelkovic M, Borovcanin M, and Djokic G
- Subjects
- Adult, Combined Modality Therapy, Exercise Test, Exercise Tolerance, Female, Hospitalization, Humans, Male, Middle Aged, Psychiatric Status Rating Scales statistics & numerical data, Psychometrics, Schizophrenia diagnosis, Treatment Outcome, Exercise psychology, Prescriptions, Schizophrenia rehabilitation, Schizophrenic Psychology
- Abstract
Background: The purpose of this study was to examine functional capacity of cardio-respiratory system in patients with schizophrenia, and to evaluate the effects of 12 weeks prescribed physical activity on aerobic capacity and symptoms of schizophrenia., Subjects and Methods: Study involved 80 hospitalized patients with any of the subtypes of schizophrenia (42 men, 38 women). They were divided into two groups: exercise and control group, both with 40 patients. Maximal aerobic capacity (VO2 max) as an indicator of cardiovascular fitness has been obtained by cardiopulmonary stress test on a treadmill. Twelve weeks program of prescribed physical activity (45 minutes, four times per week) was made for every patient individually. Patients in exercise group practiced in training zone between 65 and 75% of their maximum heart rate (HR). Target HR was controlled by Polar F4 monitors. Symptoms of schizophrenia were measured by using Positive and Negative Symptoms Scale (PANSS)., Results: Before the exercise program was introduced, measured VO2 max was significantly lower in patients with schizophrenia, than the expected average value in matched healthy subjects (p<0.001). After twelve weeks, patients in exercise group showed a significant increase of VO2max (p=0.002), and significantly higher level of VO2max compared to the control group (p=0.000). Significant differences were also observed on PANSS general psychopathology subscale (p=0.007) and on PANSS total score (p=0.001). The pharmacotherapy and exercise had influence on PANSS general psychopathology (p=0.002) and PANSS total score (p=0.001)., Conclusions: Individuals with schizophrenia have lower levels of aerobic capacity compared to general population. Prescribed physical activity significantly improves aerobic capacity in people with schizophrenia and it is effective in amelioration of some psychiatric symptoms. Prescribed physical activity could be an effective adjunctive treatment for patients with schizophrenia, not only for prevention and treatment of comorbidities, but also having an impact on symptoms of schizophrenia.
- Published
- 2017
- Full Text
- View/download PDF
20. The effect of antipsychotic drugs on nonspecific inflammation markers in the first episode of schizophrenia.
- Author
-
Stefanović V, Mihajlović G, Nenadović M, Dejanović SD, Borovcanin M, and Trajković G
- Subjects
- Adolescent, Adult, Antipsychotic Agents adverse effects, Biomarkers blood, Blood Sedimentation, Humans, Leukocyte Count, Male, Schizophrenia blood, Schizophrenia diagnosis, Schizophrenia immunology, Serbia, Time Factors, Treatment Outcome, Young Adult, Antipsychotic Agents therapeutic use, C-Reactive Protein metabolism, Inflammation Mediators blood, Schizophrenia drug therapy, Schizophrenic Psychology
- Abstract
Background/aim: Immune system disorder, including inflammation, takes a significant place when considering still unclear etiology of schizophrenia. The aim of this study was to determine the blood levels of nonspecific inflammation markers in the first episode of schizophrenia and their relation to the therapy response., Methods: In this study we determined the blood levels of nonspecific inflammation markers: white blood cells count (WBC), C-reactive protein (CRP), erythrocytes sedimentation rate (ESR) and the elements of differential white blood cell counts (or the leukocyte formula): granulocytes (Gra), lymphocytes (Lym) and monocytes (Mon), in the first episode of schizofrenia, in 78 patients hospitalized at the Clinic for Psychiatric Disorders "Dr Laza Lazarević" in Belgrade. The levels were measured at admission to the clinic, as well as after 4 weeks of antipsychotic treatment. The Positive and negative syndrome scale for schizophrenia (PANSS) was applied to measure the severity of psychopathology and response to the treatment., Results: During the first episode of schizophrenia, before initiation of antipsychotic treatment, the frequency of abnormal values was high (≥ 25% of the patients) for the following non-specific inflammation markers: WBC, CRP, ESR and Gra, in the leukocyte formula, but dropped after 4 weeks of antipsychotic treatment at the level of high statistical significance for WBC and Gra (p < 0.001). The ESR remained unchanged in as many as 50% of the patients even after 4-week antipsychotic treatment, at the level of statistical significance in the non-responders compared to the responders (p = 0.045)., Conclusion: The obtained results indicate that in the first episode of schizophrenia the blood levels of non-specific inflammation markers (WBS, CRP, ESR and Gra from the leukocyte formula) were high in the subpopulation of patients with the tendency towards normalization of inflammation parameters after a 4-week antipsychotic treatment.
- Published
- 2015
- Full Text
- View/download PDF
21. Increase systemic levels of IL-23 as a possible constitutive marker in schizophrenia.
- Author
-
Borovcanin M, Jovanovic I, Dejanovic SD, Radosavljevic G, Arsenijevic N, and Lukic ML
- Subjects
- Adolescent, Adult, Aged, Antipsychotic Agents adverse effects, Antipsychotic Agents therapeutic use, Biomarkers blood, Cytokines blood, Female, Humans, International Classification of Diseases, Male, Middle Aged, Psychiatric Status Rating Scales, Recurrence, Schizophrenia drug therapy, Schizophrenic Psychology, Young Adult, Interleukin-23 blood, Schizophrenia blood
- Abstract
Inflammation appears to play significant role in schizophrenia. IL-23 is key molecule in mediating IL-17 dependent inflammatory response. Therefore, we analyzed the serum concentrations of IL-23 levels in patients with first episode psychosis (78 subjects), in patients with acute exacerbation of schizophrenia who were already treated with antipsychotics (47 subjects) and healthy controls (35 subjects). Diagnoses were established using International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10). Psychopathology was evaluated using the Positive and Negative Syndrome Scale (PANSS) and serum levels of IL-23 were measured using sensitive enzyme-linked immunosorbent assay (ELISA). Serum levels of IL-23 were higher in patients with first psychotic episode and in patients with schizophrenia in relapse than in healthy subjects (p=0.000) and no difference was established between these two groups of patients before therapy. Also, after 4 weeks of antipsychotic therapy levels of IL-23 remains elevated in both groups of patients with no differences between two groups. It appears that increased level of IL-23 in psychotic patients independently of antipsychotic therapy can be a constitutive marker in this disorder., (Copyright © 2015 Elsevier Ltd. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
22. Antipsychotics can modulate the cytokine profile in schizophrenia: attenuation of the type-2 inflammatory response.
- Author
-
Borovcanin M, Jovanovic I, Radosavljevic G, Djukic Dejanovic S, Stefanovic V, Arsenijevic N, and Lukic ML
- Subjects
- Adult, Enzyme-Linked Immunosorbent Assay, Female, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Schizophrenia metabolism, Young Adult, Antipsychotic Agents therapeutic use, Cytokines metabolism, Schizophrenia drug therapy
- Abstract
Objective: We recently reported that the type-2 cytokine response is increased in schizophrenia. The aim of this study was to analyse the effects of antipsychotic drugs on the serum levels of type-1 (TNF-α, IFN-γ), type-2 (IL-4, IL-10), type-17 (IL-17) and regulatory cytokines (TGF-β, IL-27 and IL-6)., Methods: Cytokine measurements in the patients were performed on day 0 and day 30 of the treatment using standard ELISA assays. Three groups of subjects were studied: patients that were unmedicated with First Episode Psychosis (FEP; n=88), patients that were treated with antipsychotics with Schizophrenia in relapse (SC in relapse; n=45) and healthy controls (n=36)., Results: TGF-β levels were increased in both patient groups and were further enhanced after treatment in the FEP group (p=0.014) but not in the SC relapse group. Antipsychotic treatment was correlated with lower levels of IL-4, IL-6 and IL-27 (p<0.005) in the FEP group. Finally, the serum levels of IL-17 were not significantly altered between the two measurements but were significantly lower in the FEP group (p<0.001) when compared with healthy controls. After therapy, patients with SC who were in relapse had decreased serum levels of IL-4 (p=0.006) and IL-6 (p=0.007). We also observed a weak negative correlation between the IFN-γ/TGF-β ratio and the total PANSS score and between the IL-17/TGF-β ratio and the negative and general psychopathology subscales., Conclusion: The increased type-2 cytokine serum levels in schizophrenia appear to be downregulated by antipsychotic treatment., (Copyright © 2013 Elsevier B.V. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
23. Elevated serum level of type-2 cytokine and low IL-17 in first episode psychosis and schizophrenia in relapse.
- Author
-
Borovcanin M, Jovanovic I, Radosavljevic G, Djukic Dejanovic S, Bankovic D, Arsenijevic N, and Lukic ML
- Subjects
- Adult, Female, Humans, Interleukin-17 deficiency, Male, Psychotic Disorders diagnosis, Psychotic Disorders immunology, Schizophrenia physiopathology, Secondary Prevention, Time Factors, Cytokines blood, Cytokines classification, Interleukin-17 blood, Interleukin-4 blood, Psychotic Disorders blood, Schizophrenia blood, Schizophrenia diagnosis
- Abstract
Schizophrenia is chronic and debilitating mental disorder. In broad spectrum of possible causes or contributing factors, immune system and cytokines were investigated in the onset and development of schizophrenia. The aim of our study was to analyze the serum concentrations of type-1 cytokines: TNF-α, IFN-γ, type-2 cytokines: IL-4, IL-10, type-17 cytokine: IL-17 and regulatory cytokines: TGF-β, IL-27, IL-6, in drug-naive patients with First Episode Psychosis - FEP (n = 88) and Schizophrenia in relapse - SC in relapse patients (n = 45), comparing to healthy controls (n = 36). Also, we attempted to determine potential correlation between cytokine levels and/or cytokine ratios with clinical parameters, such as severity of illness, positive, negative and general psychopathology. Our results showed decreased levels of IL-17 (p = 0.018), demonstrating that type-17 response is blunted in psychotic episode. Increased levels of IL-4 (p = 0.033) showed that type-2 response is overweight in psychotic episode. Also, levels of IL-4 in serum of SC in relapse patients were higher than controls (p < 0.0005) and patient with FEP (p = 0.003). This alteration was accompanied with increase in production of TGF-β in psychotic patients (p = 0.009) and also in FEP (p < 0.0005) and SC in relapse (p < 0.0005). Analysis showed that TGF-β can be a valuable marker for psychosis. The presence of enhanced anti-inflammatory/immunosuppressive activity in schizophrenia may be an attempt to counteract or limit ongoing pro-inflammatory processes and downregulating chronic inflammation. Finally we have documented decreased levels of IL-17 and IL-17/TGF-β ratio in these types of psychotic patients, suggesting the new aspects of schizophrenia pathophysiology., (Copyright © 2012 Elsevier Ltd. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
24. Comparison of safety between individualized and empiric dose regimen of amitriptyline in the treatment of major depressive episode.
- Author
-
Mihajlović G, Djukić-Dejanović S, Jovanović-Mihajlović N, Janković S, Janjić V, Jovanović M, Petrović D, Borovcanin M, and Radmanović B
- Subjects
- Adverse Drug Reaction Reporting Systems, Amitriptyline adverse effects, Antidepressive Agents, Tricyclic adverse effects, Bayes Theorem, Depressive Disorder, Major diagnosis, Depressive Disorder, Major psychology, Dose-Response Relationship, Drug, Humans, Single-Blind Method, Software, Amitriptyline administration & dosage, Antidepressive Agents, Tricyclic administration & dosage, Depressive Disorder, Major drug therapy, Precision Medicine
- Abstract
To accomplish therapeutic goal it is necessary to adjust the dose of medication to be right for every single patient. This procedure of dose adjustment is individualized dose regimen. First of all, pharmacokinetic aspects should be revised, including parameters such as resorption, distribution, metabolism and secretion of drug. For these purposes, the authors developed and clinically assessed the modified Bayesian method supported by original basic computer program. The aim of research was to compare frequency of adverse events in cases of individualized and empiric dose regimens of amitriptyline in the treatment of major depressive episode. Sixty subjects (32- 65 years old), with major depressive disorder (International Classification of Disease, 10th revision), were randomly assigned and single- blinded to take individualized (experimental group, n=30) or empiric (control group, n=30) doses of amitriptyline for 8 weeks. CGI scale and originally designed questionnaire were used for adverse events assessment. In experimental group, 69 complaints on nine different types of adverse effects were recorded during eight-week treatment period. Severe adverse events, such as confusion or arrhythmia, were not registered in this subgroup. In control group, 111 complaints on twelve different types of adverse effects were recorded. Most common were anticholinergic effects, but during the third and fourth week from baseline, some severe adverse events were observed: tremor (16%), fatigue (16%), in one of the subjects confusion occurred and arrhythmia in another. Analyzing of the results according to CGI scale for adverse events showed that, during the treatment period, adverse events were less frequent in experimental group. This was particularly obvious in the first four weeks of treatment, when statistically significant difference (p<0.05) was observed.
- Published
- 2010
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.